SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-014919
Filing Date
2024-02-14
Accepted
2024-02-14 06:06:09
Documents
12
Period of Report
2024-02-13
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K lrmr-20240213.htm   iXBRL 8-K 35300
  Complete submission text file 0000950170-24-014919.txt   144318

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lrmr-20240213.xsd EX-101.SCH 23892
13 EXTRACTED XBRL INSTANCE DOCUMENT lrmr-20240213_htm.xml XML 4533
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36510 | Film No.: 24631865
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)